Dronabinol

Generic Name: Dronabinol

Brand Names: Marinol, Sativex, Syndros

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 1972-08-3

Unique Ingredient Identifier: 7J8897W37S

Background: Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication: Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions: Anorexia, Chemotherapy-Induced Nausea and Vomiting

Associated Therapies: -

Clinical Trials

Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder

Not Applicable

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2014-02-24

Last Posted Date: 2022-09-09

Lead Sponsor: Wayne State University

Target Recruit Count: 86

Registration Number: NCT02069366

Locations: 🇺🇸
Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, United States

A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis

Phase 1

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Sativex

First Posted Date: 2013-11-05

Last Posted Date: 2016-08-11

Lead Sponsor: GW Pharmaceuticals Ltd

Target Recruit Count: 10

Registration Number: NCT01975688

Locations: 🇬🇧
Quintiles London Drug Research Unit, London, United Kingdom

A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Phase 4

Completed

Conditions: Spasticity
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2013-10-17

Last Posted Date: 2023-01-12

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 121

Registration Number: NCT01964547

Locations: 🇨🇿
MS Centre, Charles University, Prague, Czechia

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

Phase 1

Completed

Conditions: Psychotic Disorder
Schizophrenia
Dual Diagnosis
Cannabis Use Disorder

Interventions: Drug: Placebo
Drug: Marijuana
Drug: Dronabinol

First Posted Date: 2013-10-17

Last Posted Date: 2021-10-13

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 261

Registration Number: NCT01964404

Locations: 🇺🇸
University of Vermont, Burlington, Vermont, United States
🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years

Phase 3

Completed

Conditions: Cerebral Palsy

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2013-07-12

Last Posted Date: 2022-12-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 72

Registration Number: NCT01898520

Locations: 🇬🇧
Center 1, London, United Kingdom
🇬🇧
Center 6, Cambridge, United Kingdom
🇨🇿
Center 14, Prague, Czechia

and more 11 locations

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Sativex

First Posted Date: 2013-06-26

Last Posted Date: 2022-12-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01887301

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States

Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.

Phase 3

Withdrawn

Conditions: Spasticity
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Sativex

First Posted Date: 2013-06-04

Last Posted Date: 2016-08-11

Lead Sponsor: GW Research Ltd

Registration Number: NCT01868048

Cannabinoids and Cerebellar-Motor Functioning

Early Phase 1

Completed

Conditions: Psychotic Disorders
Cannabis

Interventions: Drug: Placebo
Drug: THC

First Posted Date: 2013-05-14

Last Posted Date: 2022-02-11

Lead Sponsor: Yale University

Target Recruit Count: 57

Registration Number: NCT01853020

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

Phase 1

Terminated

Conditions: Schizophrenia

Interventions: Drug: Dronabinol
Other: Placebo Comparator

First Posted Date: 2013-04-16

Last Posted Date: 2015-09-21

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 13

Registration Number: NCT01832766

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Sativex

First Posted Date: 2013-03-18

Last Posted Date: 2022-12-20

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT01812603

Locations: 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧
St James's Institute of Oncology, St James's University Hospital, Leeds, Yorkshire, United Kingdom
🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy